ÂÜÀòÂÒÂ×

Torquil Jackson has a background in pharmacology and neurobiology, with experience in various roles such as Investment Analyst, Business Development Manager, and Technology Transfer and Partnerships Officer. Currently serving as a Board Observer at Verinnogen and Investment Analyst at Cancer Research Horizons, Torquil has also conducted research on Duchenne Muscular Dystrophy during their PhD at the University of Portsmouth. Prior to this, they gained experience in quality assurance at Mitsubishi Tanabe Pharma Europe Ltd.